India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Commercial real estate is entering a decade of major transformation driven by interest rate pressures, evolving work culture, rapid proptech innovation, and growing demand for AI-focused infrastructure. While the global CRE market is projected to reach $133.5 trillion by 2028, rising rates, shifting office demand, and increasing sustainability requirements are reshaping how professionals invest, manage, and develop properties. By 2030, the biggest opportunities will center on mixed‑use conversions, data center growth, premium office spaces, and ESG‑driven upgrades.
The National Association of Realtors’ landmark antitrust settlement is transforming how real estate agents negotiate compensation, work with buyers, and handle transparency in transactions. With MLS‑posted buyer‑broker commissions eliminated and written buyer agreements now required, both consumers and professionals are navigating a new, more transparent landscape. While commission levels have only dipped slightly, the real shift is in how openly compensation is discussed and negotiated—creating new challenges and opportunities for agents who adapt quickly.
Artificial intelligence is no longer a novelty in real estate — 2025 marks its breakthrough year as a dependable pillar of the proptech industry. With investors pouring capital into AI‑powered forecasting, security, automation, and property management tools, the sector is shifting from experimentation to full‑scale adoption. Brokerages, developers, and institutional players now rely on AI to streamline due diligence, enhance market modeling, reduce risk, and optimize building operations. As adoption accelerates, professionals who understand and leverage these technologies are gaining a decisive competitive edge in fast‑moving markets like Florida.
A new episode of Current Account breaks down why the insurance industry is heading into 2026 with more uncertainty — and more opportunity — than ever. From shifting global regulations and rising catastrophe risks to FSOC’s evolving role in the U.S., industry leaders Jérôme Haegeli and Philippe Brahin explain how insurers are being pushed to rethink strategy in real time. With global premium growth expected to slow and regulatory pressures rising, professionals in insurance and financial services are turning to education and new skills to stay ahead in a rapidly changing market.
New Jersey is quietly becoming one of the hottest commercial real estate markets in the nation, with Jersey City and North Jersey breaking into the top 10 in PwC’s 2026 Emerging Trends report. Fueled by redevelopment momentum, data‑center demand, mixed‑use transformations and a surge in health‑care projects, the state is drawing major investors while still battling rising construction costs and municipal fatigue. For real estate professionals, the Garden State’s evolution signals fresh opportunity—and a market worth watching closely heading into 2026.
The National Council of Insurance Legislators is pushing back against President Trump’s new executive order on artificial intelligence, arguing that it threatens decades of state‑based insurance oversight. NCOIL leaders say federal attempts to centralize AI authority could disrupt markets, weaken consumer protections, and limit states’ ability to innovate—setting the stage for a significant legal and political battle with major implications for insurance professionals who rely on AI‑driven tools and regulatory clarity.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
